Skip to main navigation

Compass Therapeutics

Home
About
Platform
Pipeline
Clinical Trials
Join Us
Investors
Contact

News Releases

Investor Menu

Home
News & Events
Stock Information
Corporate Governance
Financial & FIlings

Year

May 28, 2026

Compass Therapeutics to Participate in Upcoming June Investor Events

Additional Formats

PDF Version

May 21, 2026

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting

Additional Formats

PDF Version

May 12, 2026

Compass Therapeutics to Participate in Upcoming May Investor Events

Additional Formats

PDF Version

May 05, 2026

Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update

Additional Formats

PDF Version

Apr 27, 2026

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Additional Formats

PDF Version

Apr 24, 2026

Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer

Additional Formats

PDF Version

Mar 05, 2026

Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update

Additional Formats

PDF Version

Jan 06, 2026

Compass Therapeutics Provides Corporate Update

Additional Formats

PDF Version

Jan 05, 2026

Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Additional Formats

PDF Version

Jan 05, 2026

Compass Therapeutics Announces Key Leadership Appointments

Additional Formats

PDF Version

IR Contact

IR@compasstherapeutics.com

Media Contact

Anna Gifford, Chief of Staff

Anna.Gifford@compasstherapeutics.com

Email Alerts

© 2026 Compass Therapeutics, Inc.
Terms & Conditions
Privacy Policy

Home
About
Platform
Pipeline
Clinical Trials
Join Us
Investors
Contact